Akers生物科学 AKER 深 沪
等待开盘 12-15 09:30:00 美东时间
2.47
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 2.47
- 总市值 4113.24万
- 52周最高 41820.00
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 9900.00
- 委 比 0.00%
- 总股本 1665.28万
- 历史最高 6566400.00
- 量 比 0
- 振 幅 0.00%
- 历史最低 5760.00
- 每 手 1
- 风险率 0.25%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Akero Therapeutics to be Acquired by Novo Nordisk for up to $5.2 Billion
Akero Therapeutics will be acquired by Novo Nordisk for up to $5.2 billion in cash. Akero shareholders will receive $54.00 per share in cash and a Contingent Value Right (CVR) of $6.00 per share upon U.S. regulatory approval of efruxifermin (EFX) for treating MASH-related cirrhosis by 2031. The deal includes a 19% premium to Akero’s 30-day VWAP and a 42% premium to its May 19, 2025 closing price. Akero's EFX program aims to address MASH, and the ...
10-09 10:01
Akero Therapeutics to Present New Data from the Phase 2b SYMMETRY and HARMONY Studies of Efruxifermin at the 76th Annual AASLD The Liver Meeting® 2025
Akero Therapeutics announced upcoming oral and poster presentations at the 76th AASLD Liver Meeting 2025 in Washington, DC. The presentations will highlight results from the 96-week Phase 2b SYMMETRY study assessing efruxifermin (EFX) in patients with compensated cirrhosis due to metabolic dysfunction-associated steatohepatitis (MASH). Key findings include improvements in non-invasive fibrosis regression markers and portal hypertension, as well a...
10-07 11:00
Akero Therapeutics Announces Lancet Publication of the Phase 2b HARMONY Clinical Trial Demonstrating 96 Weeks Treatment with EFX Reduced Liver Fibrosis in Patients with Pre-cirrhotic MASH
Results from Akero Therapeutics' Phase 2b HARMONY trial, published in *The Lancet*, demonstrate that efruxifermin (EFX) significantly reduced liver fibrosis and resolved steatohepatitis in patients with pre-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH). At 96 weeks, 49% of participants on 50mg EFX achieved fibrosis improvement without worsening of MASH, compared to 19% on placebo. Additionally, EFX improved liver injury marker...
08-14 22:30
【监管】赶紧卸载！这33款App被通报→
市市场监管局介绍，依据《网络安全法》《个人信息保护法》等法律法规，按照《中央网信办、工业和信息化部、公安部、市场监管总局关于开展2025年个人信息保护系列专项行...
07-29 12:11
官方通报！涉嫌违规，义乌人抓紧自查！
（来源：爱义乌） 近日 据国家网络安全通报中心通报 33款移动应用 存在违法违规收集 使用个人信息情况 其中 驾校宝典、扫描全能王等App在列 快看看有没有...
07-25 19:02
违法违规收集使用个人信息，33款移动应用被通报
转自：北京日报客户端 依据《网络安全法》《个人信息保护法》等法律法规，按照《中央网信办、工业和信息化部、公安部、市场监管总局关于开展2025年个人信息保护系列...
07-23 17:03
Akebia Therapeutics to Present at the H.C. Wainwright 4th Annual Kidney Virtual Conference
Akebia Therapeutics, Inc., a biopharmaceutical company focused on improving lives of kidney disease patients, announced that its Chief Commercial Officer, Nik Grund, will participate in a Fireside Chat at the H.C. Wainwright 4th Annual Kidney Virtual Conference on July 14 at 10:00 AM EDT. A webcast of the presentation will be available on Akebia's website following the event.
07-08 12:00
创新创业通识课报名｜康文胜：双重身份“过来人”视角漫谈创业和投融资
创燃未来 • INNOVATE X 2025.6.6 {创新创业系列活动} 第二期 Vol.02 通识课程 TOPIC 创业路上总在交学费 如何...
06-05 17:31
